Biocardia stock.

Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...BioCardia announces $1.3M registered direct offering priced at-the-market. Track BioCardia Inc. (BCDA) Stock Price, Quote, latest community messages, chart, news …Nov 8, 2023 · BioCardia Reports First Quarter 2023 Business Highlights and Financial Results. BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications. BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023. Complete BioCardia Inc. stock information by Barron's. View real-time BCDA stock price and news, along with industry-best analysis.

Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled ...BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million.BCDAW | Complete BioCardia Inc. Wt stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today …BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart F. Find the latest BioCardia, Inc. (BCDA) stock quote, …

Dec 1, 2023 · Earnings for BioCardia are expected to decrease in the coming year, from ($0.54) to ($0.56) per share. BioCardia has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More. Peter Altman became the CEO of BioCardia, Inc. (NASDAQ:BCDA) in 2002, and we think it's a good time to look at the...On November 15, 2023, BioCardia achieved a major breakthrough as it obtained FDA authorization for its groundbreaking CardiAMP Heart Failure ... BCDA stock has shown promising performances on November 15, 2023, with positive price forecasts and a consensus among analysts to buy the stock. However, investors should conduct further …Get the latest BioCardia Inc (BCDA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Sep 5, 2023 · SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

Tiger X Medical Inc (ZB_14248869.) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Tiger X Medical Inc | Other OTC: | Other OTC ... BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell ...

The estimated Net Worth of Peter Altman is at least $747 Mille dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $69,056 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer e Director at BioCardia.

Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.BioCardia's stock was trading at $0.8269 at the start of the year. Since then, BCDAW stock has decreased by 86.7% and is now trading at $0.11. View the best growth stocks for 2023 here. This page (NASDAQ:BCDAW) was last updated on 10/17/2023 by MarketBeat.com Staff. Get 30 Days of MarketBeat All Access Free.The BioCardia, Inc. stock price fell by -0.92% on the last day (Wednesday, 29th Nov 2023) from $0.686 to $0.680. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 11.30% from a day low at $0.639 to a day high of $0.711. The price has fallen in 8 of the last 10 days and is down by -36.45% for this period.BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...Nov 14, 2023 · SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ... Nov 14, 2023 · Health Topics mentioned in this article. The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart ...

The Wall Street analyst predicted. that Biocardia's share price could reach $4.00 by Nov 14, 2024. The average Biocardia stock price prediction forecasts a potential upside of 495.24% from the current BCDA share price of $0.67.Nov 7, 2023 · BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42. Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.Nov 24, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for BioCardia stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for BCDA. The average twelve-month price prediction for BioCardia is $4.00 with a high price target of $4.00 and a low price target of $4.00. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. (GlobeNewswire) -15.27%. Nov-15-23 11:04AM. BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study.

The estimated Net Worth of Peter Altman is at least $913 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $235,166 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.Stock Performance. Shares of BioCardia were trading at $0.405 as of November 06. Over the last 52-week period, shares are down 78.11%. Given that these returns are generally negative, long-term ...

BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in fourth quarter 2024.Allan Tessler BCDA stock SEC Form 4 insiders trading. Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.400 units of BCDA stock worth $199,200 on 9 March 2020.8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.16 Nov 2023 ... BioCardia develops cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Stock BCDA logo. BioCardia ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%?Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...

Nov 16, 2023 · SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE …

BioCardia's stock was trading at $0.8269 at the start of the year. Since then, BCDAW stock has decreased by 86.7% and is now trading at $0.11. View the best growth stocks for 2023 here. This page (NASDAQ:BCDAW) was last updated on 10/17/2023 by MarketBeat.com Staff. Get 30 Days of MarketBeat All Access Free.What this means: Biocardia Inc (BCDA) gets an Overall Rank of 53, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.$1.0401 0.6411 [160.68%] Last update: 4:12PM (Delayed 15-Minutes) Get Real Time Here $1.0401 0 [0.00%] Profile News Analyst Ratings Guidance Dividends …The estimated Net Worth of Peter Altman is at least $883 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $205,985 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesThe estimated Net Worth of Peter Altman is at least $875 mil dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $197,402 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer y Director at BioCardia.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...Sep 5, 2023 · The latest update sent BioCardia’s stock down around 20% to 62 cents in premarket trading, adding to losses that have seen the share price slide by more than 60% in six months. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire)-15.27%. Nov-15-23 11:04AM BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of …

Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...Nov 29, 2023 · A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The estimated Net Worth of Peter Altman is at least $849 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.See the latest BioCardia Inc stock price (BCDA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Instagram:https://instagram. uaw wages 2023 per hourrusseell 2000best personal investment companiesrigquote The estimated Net Worth of Peter Altman is at least $849 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ... ny state capital gains taxiso coin The estimated Net Worth of Peter Altman is at least $849 Tausend dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer und Director at BioCardia. is vsp good vision insurance SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...12 Okt 2023 ... What's more, Peter Altman holds US$224k worth of shares in the company in their own name. Component, 2022, 2021, Proportion (2022). Salary, US ...Nov 7, 2023 · BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42.